AMGN
Amgen Inc. NASDAQ Listed Jun 17, 1983$329.06
Mkt Cap $177.6B
52w Low $261.43
52.1% of range
52w High $391.29
50d MA $354.66
200d MA $325.35
P/E (TTM)
23.0x
EV/EBITDA
14.0x
P/B
20.5x
Debt/Equity
6.3x
ROE
89.1%
P/FCF
21.7x
RSI (14)
—
ATR (14)
—
Beta
0.47
50d MA
$354.66
200d MA
$325.35
Avg Volume
2.7M
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
One Amgen Center Drive · Thousand Oaks, CA 91320-1799 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | 4.77 | 5.15 | +8.0% | 346.25 | -4.0% | -4.7% | -6.5% | -4.8% | -4.4% | -5.0% | — |
| Feb 3, 2026 | AMC | 4.73 | 5.29 | +11.8% | 338.59 | +4.0% | +8.2% | +8.6% | +13.5% | +11.0% | +7.7% | — |
| Nov 4, 2025 | AMC | 5.02 | 5.64 | +12.4% | 296.70 | +2.2% | +7.8% | +6.4% | +7.9% | +9.1% | +14.1% | — |
| Aug 5, 2025 | AMC | 5.28 | 6.02 | +14.0% | 300.08 | -1.5% | -5.1% | -5.1% | -3.9% | -5.0% | -5.0% | — |
| May 1, 2025 | AMC | 4.27 | 4.90 | +14.8% | 283.78 | +2.7% | -0.9% | -1.3% | -4.7% | -2.8% | -4.1% | — |
| Feb 4, 2025 | AMC | 5.04 | 5.31 | +5.4% | 289.02 | +0.6% | +6.5% | +3.0% | +1.6% | +2.0% | +2.6% | — |
| Oct 30, 2024 | AMC | 5.11 | 5.58 | +9.2% | 315.54 | +0.7% | +1.5% | +1.2% | +0.4% | +1.2% | +2.0% | — |
| Aug 6, 2024 | AMC | 4.98 | 4.97 | -0.2% | 328.95 | -2.4% | -5.0% | -1.3% | -2.0% | -2.7% | -1.7% | — |
| May 2, 2024 | AMC | 3.88 | 3.96 | +2.1% | 278.39 | +12.6% | +11.8% | +7.6% | +7.9% | +10.4% | +12.4% | — |
| Feb 6, 2024 | AMC | 4.59 | 4.71 | +2.6% | 316.07 | -0.2% | -6.4% | -6.7% | -7.9% | -6.8% | -8.1% | — |
| Oct 31, 2023 | AMC | 4.65 | 4.96 | +6.7% | 255.70 | +0.2% | +2.0% | +4.3% | +5.5% | +6.7% | +6.0% | — |
| Aug 3, 2023 | AMC | 4.44 | 5.00 | +12.6% | 230.70 | +3.1% | +5.5% | +9.6% | +13.0% | +12.4% | +13.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5 | Erste Group | Downgrade | Buy → Hold | — | $323.85 | $321.91 | -0.6% | +1.8% | +2.2% | +1.6% | — | — |
| May 1 | Truist | Maintains | Hold → Hold | — | $346.25 | $332.52 | -4.0% | -4.7% | -6.5% | -4.8% | -4.4% | -5.0% |
| Apr 21 | Canaccord Genuity | Initiates | Hold | $366 | $350.16 | $350.23 | +0.0% | -1.5% | -1.2% | -0.4% | -1.6% | -2.9% |
| Apr 13 | UBS | Maintains | Buy → Buy | — | $351.02 | $352.09 | +0.3% | -0.3% | -0.0% | -0.8% | -0.5% | +1.2% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $355.60 | $357.46 | +0.5% | -1.3% | -1.6% | -1.3% | -2.1% | -1.7% |
| Apr 9 | Guggenheim | Maintains | Neutral → Neutral | — | $349.81 | $347.46 | -0.7% | +1.7% | +0.3% | +0.0% | +0.3% | -0.5% |
| Apr 8 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $340.00 | $345.61 | +1.6% | +2.9% | +4.6% | +3.2% | +2.9% | +3.2% |
| Feb 19 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $379.73 | $377.91 | -0.5% | -1.1% | -1.3% | -0.1% | +0.8% | +1.2% |
| Feb 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $373.36 | $373.50 | +0.0% | +1.7% | +0.6% | +0.4% | +1.6% | +2.5% |
| Feb 12 | Freedom Broker | Downgrade | Buy → Hold | — | $366.58 | $366.66 | +0.0% | -0.1% | +0.7% | +1.8% | +3.6% | +2.4% |
| Feb 6 | Guggenheim | Maintains | Neutral → Neutral | — | $367.80 | $369.99 | +0.6% | +4.5% | +2.2% | -0.9% | -0.3% | -0.4% |
| Feb 6 | Argus | Maintains | Buy → Buy | — | $367.80 | $369.99 | +0.6% | +4.5% | +2.2% | -0.9% | -0.3% | -0.4% |
| Feb 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $338.59 | $352.03 | +4.0% | +8.2% | +8.6% | +13.5% | +11.0% | +7.7% |
| Feb 4 | Leerink Partners | Maintains | Outperform → Outperform | — | $338.59 | $352.03 | +4.0% | +8.2% | +8.6% | +13.5% | +11.0% | +7.7% |
| Feb 4 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $338.59 | $352.03 | +4.0% | +8.2% | +8.6% | +13.5% | +11.0% | +7.7% |
| Feb 4 | Citigroup | Maintains | Neutral → Neutral | — | $338.59 | $352.03 | +4.0% | +8.2% | +8.6% | +13.5% | +11.0% | +7.7% |
| Jan 26 | UBS | Maintains | Buy → Buy | — | $344.75 | $344.70 | -0.0% | +1.4% | +1.9% | -0.7% | -0.5% | -0.8% |
| Jan 20 | Bernstein | Downgrade | Outperform → Market Perform | — | $330.41 | $325.58 | -1.5% | +0.2% | +4.0% | +5.0% | +4.3% | +5.8% |
| Jan 8 | Truist | Maintains | Hold → Hold | — | $341.64 | $337.76 | -1.1% | -3.4% | -4.5% | -4.7% | -5.1% | -3.7% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $317.38 | $317.30 | -0.0% | +0.1% | +2.5% | +2.9% | +2.7% | +2.2% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $313.85 | $316.25 | +0.8% | +0.5% | +1.1% | +1.2% | +3.7% | +4.1% |
| Dec 3 | BMO Capital | Maintains | Outperform → Outperform | — | $338.36 | $340.54 | +0.6% | +2.1% | +0.5% | -2.5% | -5.1% | -7.2% |
| Nov 27 | Leerink Partners | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Nov 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $336.00 | $336.74 | +0.2% | +0.2% | +1.7% | +2.4% | +1.9% | +0.0% |
| Nov 12 | Freedom Broker | Maintains | Hold → Hold | — | $338.45 | $338.64 | +0.1% | -0.6% | -0.7% | -0.5% | +1.0% | +1.6% |
| Nov 6 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $319.86 | $319.10 | -0.2% | -1.3% | +0.1% | +1.2% | +5.8% | +5.1% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $296.70 | $303.13 | +2.2% | +7.8% | +6.4% | +7.9% | +9.1% | +14.1% |
| Nov 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $296.70 | $303.13 | +2.2% | +7.8% | +6.4% | +7.9% | +9.1% | +14.1% |
| Sep 26 | BofA Securities | Maintains | Underperform → Underperform | — | $271.18 | $274.34 | +1.2% | +0.7% | +1.0% | +4.1% | +10.1% | +9.7% |
| Aug 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $293.72 | $292.61 | -0.4% | -1.8% | -1.4% | -2.0% | -2.8% | -2.0% |
| Aug 6 | UBS | Maintains | Neutral → Neutral | — | $300.08 | $295.51 | -1.5% | -5.1% | -5.1% | -3.9% | -5.0% | -5.0% |
| Aug 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $300.08 | $295.51 | -1.5% | -5.1% | -5.1% | -3.9% | -5.0% | -5.0% |
| Aug 6 | Citigroup | Maintains | Neutral → Neutral | — | $300.08 | $295.51 | -1.5% | -5.1% | -5.1% | -3.9% | -5.0% | -5.0% |
| Jul 23 | BofA Securities | Maintains | Underperform → Underperform | — | $305.69 | $307.81 | +0.7% | +1.2% | +0.9% | +0.3% | -1.4% | -0.7% |
| Jul 22 | Citigroup | Maintains | Neutral → Neutral | — | $295.87 | $296.46 | +0.2% | +3.3% | +4.5% | +4.3% | +3.6% | +1.8% |
| Jul 21 | UBS | Maintains | Neutral → Neutral | — | $294.76 | $294.75 | -0.0% | +0.4% | +3.7% | +4.9% | +4.7% | +4.0% |
| Jun 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $279.11 | $278.57 | -0.2% | -0.7% | +0.0% | +4.1% | +6.4% | +6.9% |
| Jun 24 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $272.44 | $273.13 | +0.3% | +1.9% | +2.9% | +2.4% | +1.7% | +2.5% |
| May 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $271.69 | $270.66 | -0.4% | +0.3% | +1.5% | +1.2% | -0.1% | +0.1% |
| May 7 | Mizuho | Maintains | Neutral → Neutral | — | $270.44 | $272.03 | +0.6% | +2.0% | +0.6% | -1.7% | +1.6% | +0.0% |
| May 2 | UBS | Maintains | Neutral → Neutral | — | $283.78 | $291.50 | +2.7% | -0.9% | -1.3% | -4.7% | -2.8% | -4.1% |
| May 2 | RBC Capital | Maintains | Outperform → Outperform | — | $283.78 | $291.50 | +2.7% | -0.9% | -1.3% | -4.7% | -2.8% | -4.1% |
| Apr 14 | UBS | Maintains | Neutral → Neutral | — | $285.98 | $286.77 | +0.3% | +2.8% | +3.3% | -1.2% | -3.0% | -4.3% |
| Apr 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $280.26 | $268.91 | -4.0% | +3.9% | +0.4% | +2.0% | +4.9% | +5.4% |
| Mar 5 | BofA Securities | Maintains | Underperform → Underperform | — | $312.19 | $310.63 | -0.5% | +1.4% | +1.8% | +4.1% | +4.9% | +2.1% |
| Feb 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $293.54 | $296.88 | +1.1% | +0.4% | +1.1% | +0.5% | +1.2% | -0.8% |
| Feb 6 | BofA Securities | Maintains | Underperform → Underperform | — | $307.81 | $309.49 | +0.5% | -3.3% | -4.6% | -4.2% | -3.6% | -4.1% |
| Feb 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $289.02 | $290.69 | +0.6% | +6.5% | +3.0% | +1.6% | +2.0% | +2.6% |
| Jan 29 | BMO Capital | Maintains | Outperform → Outperform | — | $280.30 | $280.03 | -0.1% | +0.5% | +1.3% | +1.8% | +3.1% | +3.1% |
| Jan 28 | Citigroup | Maintains | Neutral → Neutral | — | $282.95 | $280.13 | -1.0% | -0.9% | -0.4% | +0.4% | +0.9% | +2.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Grygiel Nancy A.Off | SVP & CCO | Sell | 1,237 | $323.73 | $400K | 7,009 | +0.46% | — |
8-K · 5.02
!!! Very High
Amgen Inc -- 8-K 5.02: Executive Change
Amgen is redistributing its Chief Technology Officer role among existing executives following Robert Reese's retirement, streamlining leadership structure around science and commercial integration.
Apr 22
8-K · 5.02
!!! Very High
Tivic Health Systems, Inc. -- 8-K 5.02: Executive Change
Tivic Health Systems appointed Michael K. Handley as Chief Executive Officer, signaling leadership transition that investors should monitor for strategic direction changes and operational impact.
Mar 4
8-K
Amgen Inc -- 8-K Filing
Amgen issued $6 billion in senior notes across four tranches maturing 2031-2056 with rates ranging from 4.2% to 5.65%, providing long-term debt financing at competitive rates.
Feb 19
8-K
Amgen Inc -- 8-K Filing
Amgen uses non-GAAP metrics like adjusted EBITDA and debt leverage ratios to supplement GAAP reporting, allowing investors to better assess operational performance and financial health beyond standard accounting measures.
Feb 3
Data updated apr 24, 2026 5:46pm
· Source: massive.com